At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 307 enrolled
Drug / intervention
maribavir +1 moredrug
Likely dose
maribavir 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants
In Brief
A Phase 3 clinical trial evaluating maribavir and ganciclovir for Cytomegalovirus Infections. Completed, enrolled 307 participants across 55 sites.
Detailed Summary
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a liver transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infections
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartJul 2007
Primary CompletionSep 2009
TodayJul 2026
First PostedJul 9, 2007
Enrollment StartJul 23, 2007
Primary CompletionSep 14, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.0 years ago
Interventions
maribavirdrug
100mg twice a day for 14 weeks.
ganciclovirdrug
1000mg three times per day for 14 weeks.